Circulation researchJul 16, 2026

Protecting the Heart by Preventing Blood Vessel Aging with GLP-1 Receptor Agonists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 17, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with improved vascular regenerative progenitor cell flux in type 2 diabetes.

GLP-1RAs have shown a class-wide reduction in major adverse cardiovascular events in various trials.
Recent findings suggest GLP-1RAs may be effective in treating atherosclerosis, heart failure, and peripheral artery disease.
There is emerging interest in the potential of GLP-1RAs for chronic kidney disease management.
The use of GLP-1RAs may address three key aspects of vascular aging: stem cell exhaustion, altered communication between cells, and chronic inflammation.
Imbalances in blood cell formation during cardiometabolic diseases could worsen chronic inflammation and speed up vascular aging.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of type 2 diabetes and obesity. Due to class-wide reduction in major adverse cardiovascular events in cardiovascular outcome trials and pleiotropic actions in multiple tissues, the use of GLP-1RAs has expanded beyond metabolic diseases. Recent studies have reported GLP-1RA efficacy for the treatment of atherosclerosis, heart failure and peripheral artery disease, alongside evolving potential in chronic kidney disease. The recent discovery that GLP-1RAs can improve vascular regenerative progenitor cell flux during type 2 diabetes has uncovered a novel mechanism implicating 3 classical hallmarks of vascular aging: (1) stem cell exhaustion, (2) altered intercellular communication, and (3) chronic systemic inflammation. In this review we discuss recent evidence demonstrating that imbalances in hematopoiesis during cardiometabolic diseases intersect with the senescence-associated secretory phenotype to elevate chronic inflammation and accelerate vascular aging. With a focus on stem cells as the master regulators of regenerative processes, we integrate the activities of GLP-1RAs that shift the balance from damage accumulation to repair competence in blood vessels prematurely aged by cardiometabolic syndrome.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

H. Teoh reports receiving personal fees from the Canadian Medical and Surgical Knowledge Translation Research Group and LMC Healthcare. K.A. Connelly reports receiving grants, research support, speaking honoraria, or acting as an advisor for Abbott, AstraZeneca, Boehringer Ingelheim, Canadian Heart Research center, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, NovoNordisk, Sanofi, Servier, and Servier; and holds a patent with Boehringer Ingelheim for the medical use of linagliptin for heart failure with preserved ejection fraction. S. Verma reports receiving grants, research support, speaking honoraria, or acting as an advisor for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Heart Research center, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics Inc., Humber River Health, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management Inc., Sanofi and Sun Pharma. The other authors report no conflicts.

PubMed

Protecting the Heart by Preventing Blood Vessel Aging with GLP-1 Receptor Agonists

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief